Researchers from UPMC Hillman Cancer Center and colleagues published their results from the CAMILLA trial showing that combining cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer is a promising treatment, potentially expanding treatment options for patients with microsatellite stable…
It is common practice for clinicians to administer granulocyte colony-stimulating factor (G-CSF) — a growth factor used to replenish white blood cell counts — during chemotherapy, but what are its effects on overall survival in patients with pancreatic cancer? …
The University of Pittsburgh was awarded a five-year grant from the National Institutes of Health (NIH) to support an Ovarian Cancer Specialized Program of Research Excellence (SPORE). The award is led by Ronald Buckanovich, MD, PhD, and Robert Edwards, MD. Dr. Buckanovich is a professor…
Clarivate™ has named their list of Highly Cited Researchers for 2023 — an elite group that demonstrates significant and broad influence in their field of research. Each researcher selected has authored multiple Highly Cited Papers™, which rank in the top…
University of Pittsburgh researchers at UPMC Hillman Cancer Center are working to better understand breast cancer to help with the diagnosis, treatment, and prevention of the disease. For example, they are examining the effects of hormones such as estrogen on…
Saturday, September 30 1:22 – 1:42 p.m. Non Definitive Lung Options: Palliation and XRT Alone Location: Room 33 Uzoma Iheagwara, MD, PhD – UPMC Hillman Cancer Center Sunday, October 1 8 – 9 a.m. SS 02 – GYN 1: Integrating…
Published in Science Immunology, researchers led by Dario Vignali, PhD, distinguished professor and chair of the Department of Immunology and member of UPMC Hillman Cancer Center, identified a genetic mechanism to enhance an immune system’s antitumor activity. By finding a…
Benjamin A. Nacev, MD, PhD, assistant professor of medicine in the Division of Hematology/Oncology, has been named a Damon Runyon Clinical Investigator by the Damon Runyon Cancer Research Foundation. With his mentor, Jeremy Rich, MD, Dr. Nacev will receive $600,000…
Friday, June 2 Posters Divya Natesan “Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network” 8 to 11 a.m. Hall A | Abstract 2592 | Board 434 Jingxiao Jin, MD…
Researchers have known that microorganisms in the gut can impact the effectiveness of immunogenic chemotherapies for cancer patients. When studies showed that the same could be true for immune checkpoint inhibitors, it opened the possibility for better treatment options for…
